Herantis, Renishaw Collaborate on Parkinson’s Study
News Oct 25, 2016
Herantis Pharma plc and Renishaw plc have signed a collaboration agreement related to the first clinical study of CDNF in Parkinson’s disease. Under the agreement, the Drug Delivery System developed by Renishaw will be used for the clinical administration of CDNF. Herantis and Renishaw will jointly contribute to funding of the clinical study and both companies expect to independently benefit from the clinical data on CDNF and Drug Delivery System respectively.
“Collaboration with Renishaw is extremely valuable for us,” says Sigrid Booms, Herantis’ Director for Clinical Research. “In addition to benefitting from their novel and innovative technology in the clinical study we will also get the expertise and resources of an experienced global company.”
Herantis and Renishaw are also partners in a consortium currently preparing an approximately €6 million grant agreement with the EU’s Horizon 2020 framework programme related to the clinical study. Clinical trial applications have been submitted to regulatory authorities. Due to prolonged regulatory processes and ongoing EU grant negotiations the study’s planned launch of patient recruitment has been postponed from end of 2016 to the first half of 2017.
Scientists have discovered that defective astrocytes are linked to the buildup of a toxic protein that is one the hallmarks of Parkinson's disease. The studied astrocytes, derived from Parkinson's disease patients with a genetic mutation that affects cell clean-up functions, caused more accumulation of the toxin, α -synuclein, than those derived from healthy individuals.READ MORE
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019